Why compare them?
Both are represented in Weight management and Type 2 diabetes research, making their overlapping mechanisms and evidence maturity useful to compare.
Simple first. Deeper when you want it.
Understand the differences that matter.
See the biggest similarities, differences, strengths, limitations, and unanswered questions first—then open the evidence behind them.
Compound comparison
Liraglutide vs. CagriSema
Understand the meaningful overlap, differences, evidence, and unknowns—then go deeper only when you want to.
60-Second Summary
The answer first
Current evidenceComparable evidence base
No direct head-to-head study is represented. This comparison uses separate evidence records that may differ in population, duration, route, dose, and endpoint.
✓ Shared
Shared Similarities
- Both records include GLP-1R.
- Both have been studied in Weight management and Type 2 diabetes.
- Both have controlled human research, although the questions and designs may differ.
⇄ Different
Biggest Difference
Liraglutide is distinguished by single GLP-1 receptor agonist with once-daily approved injection products and a long human evidence record; CagriSema is distinguished by a fixed-dose combination: cagrilintide adds amylin-related signaling while semaglutide adds GLP-1 receptor agonism. Its outcomes belong to the combination, not either component alone.
? Unknown
Biggest Unknown
No direct head-to-head study establishes how these compounds compare under the same population, dose, duration, and endpoints.
Key Takeaways
Liraglutide is distinguished in the current record by single GLP-1 receptor agonist with once-daily approved injection products and a long human evidence record. CagriSema is distinguished by a fixed-dose combination: cagrilintide adds amylin-related signaling while semaglutide adds GLP-1 receptor agonism. Its outcomes belong to the combination, not either component alone. Neither is objectively “better”; the useful question is which evidence record addresses the research question being asked.
Research matrix
Which question has stronger current support?
Research questionStronger current supportExplanation
Human evidenceLiraglutide
Liraglutide: Mature human evidence. CagriSema: Strong Phase 3 evidence.
Regulatory historyLiraglutide
Liraglutide: FDA approved for defined product-specific indications. CagriSema: Investigational — U.S. application under review.
Mechanistic breadthCagriSema
More named targets describes mechanistic breadth; it does not establish greater effectiveness.
Direct comparisonUnknown
Separate studies cannot establish comparative superiority.
Deeper when you want it
Explore the evidence and nuance
Best-studied areas and pathway mapSee shared targets, unique pathways, and the research questions attached to each record.
Liraglutide
- Weight management
- Type 2 diabetes
- Cardiovascular outcomes
- Adolescent obesity
CagriSema
- Weight management
- Type 2 diabetes
- Glycemic control
- Add-on therapy to basal insulin
Pathway and research map
Shared foundation and unique questions
Research confidence by questionCompare regulatory, human-evidence, outcome, and administration records side by side.
Question by question
What each evidence base can actually answer
Regulatory statusEvidence, not a winner
LiraglutideFDA-labeled indications
FDA approved in product-specific daily injection formulations for chronic weight management, type 2 diabetes, and cardiovascular-risk reduction in a defined diabetes population.
CagriSemaApplication under review
Investigational. The sponsor submitted a U.S. new drug application for weight management in December 2025; no FDA approval or final product label was identified through July 25, 2026.
Evidence depthEvidence, not a winner
LiraglutideMature Phase 3 + outcomes
Multiple randomized Phase 3 trials and the 9,340-participant LEADER cardiovascular outcomes trial, with adult and pediatric product-specific evidence.
CagriSemaMultiple Phase 3 trials
Two large peer-reviewed Phase 3 weight-management trials, three additional peer-reviewed Phase 3 diabetes trials, direct semaglutide and cagrilintide active comparisons, and a blood-pressure secondary analysis.
Weight outcomesEvidence, not a winner
LiraglutidePeer-reviewed Phase 3
SCALE reported −8.4 kg mean change at 56 weeks versus −2.8 kg placebo. STEP 8 directly compared liraglutide 3.0 mg with semaglutide 2.4 mg.
CagriSemaPeer-reviewed Phase 3
REDEFINE 1 reported −20.4% mean change versus −3.0% placebo without diabetes. REDEFINE 2 reported −13.7% versus −3.4% in adults with type 2 diabetes, both under treatment-policy estimands.
Type 2 diabetesEvidence, not a winner
LiraglutideApproved + pediatric trial
Victoza has extensive adult evidence and controlled pediatric evidence beginning at age 10. Product-specific labeled doses differ from weight-management use.
CagriSemaFour Phase 3 datasets
REDEFINE 2 and REIMAGINE 1, 2, and 3 demonstrated glycemic improvements across obesity, diet-only, oral-medication, and basal-insulin type 2 diabetes populations.
Obstructive sleep apnoeaEvidence, not a winner
LiraglutideControlled study; not approved
A 359-participant trial found a larger reduction in apnea–hypopnea index than placebo, but no U.S. liraglutide OSA indication was identified.
CagriSemaNo dedicated evidence
No dedicated completed controlled human obstructive-sleep-apnoea outcome trial was located by the cutoff.
Cardiovascular outcomesEvidence, not a winner
LiraglutideLEADER + labeled use
LEADER found fewer major cardiovascular events in adults with type 2 diabetes and high cardiovascular risk, supporting a defined Victoza indication.
CagriSemaBP analysis; outcomes pending
A REDEFINE 1 secondary analysis found larger blood-pressure reductions than placebo. That is not a cardiovascular-outcomes trial, and long-term cardiovascular and renal outcomes remain unresolved.
Administration and handlingEvidence, not a winner
LiraglutideDaily product-specific injection
Current approved products are once-daily subcutaneous, ready-to-use solutions. Saxenda and Victoza have different labeled dose ranges, purposes, and instructions.
CagriSemaTrial descriptions only
Trials describe once-weekly subcutaneous administration under protocol-specific escalation. CagriSema has no approved consumer dose, schedule, reconstitution method, or storage instructions.
Comparison limitationsUnderstand what this comparison cannot establish before interpreting separate studies.
Comparable evidence base
- No direct head-to-head trial is represented for this pair.
- Separate studies may use different populations, endpoints, durations, doses, routes, and estimands.
- Results should not be interpreted as comparative superiority or individual guidance.
Current unknowns
Questions the evidence cannot answer yet
- Long-term comparative outcomes versus newer weekly incretin therapies and whether narrower research findings become approved uses.
- The FDA decision and final label, long-term cardiovascular and renal outcomes, rare events, and durability after discontinuation.
Community Intelligence
Emerging patterns, clearly separated from evidence
Liraglutide
No community experiences yetBe the first account holder to contribute.
CagriSema
No community experiences yetBe the first account holder to contribute.
Community Intelligence summarizes structured, self-reported experiences. It can reveal patterns and useful research questions, but it cannot prove safety, effectiveness, or cause and effect. Published evidence is always shown separately.